Vascular Endothelial Growth Factor (VEGF) Articles

BERKELEY, CA (UroToday.com) -

Drug Tolerability in the Choice of Second-Line Therapy for Metastatic Renal Cell Carcinoma

Early diagnosis of prostate cancer (PCa) is critical for the prevention of metastasis and for early treatment; therefore, a simple and accurate device must be developed for this purpose. In this study, we reported a novel fabrication method for producing a dual-modality biosensor that can simultaneously detect vascular endothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early diagnosis of PCa.

Vascular endothelial growth factor (VEGF) is essential for normal embryonic development, and maintenance of adult vascular function. Originally described as a vascular permeability factor, VEGF alters tight cell junctions and contributes to maintenance of bladder permeability.

BERKELEY, CA (UroToday.com) - Almost a decade ago, systemic treatment options for metastatic renal cell carcinoma (mRCC) were limited to cytokine therapy (interleukin and interferon). Those treatments had modest benefit, albeit, significant toxicities.^{[1, 2]}

Targeting the vascular endothelial growth factor (VEGF) pathway has improved outcomes in metastatic renal cell carcinoma (RCC); however, resistance inevitably occurs. CD105 (endoglin) is an angiogenic pathway that is strongly upregulated after VEGF inhibition, potentially contributing to resistance.

BERKELEY, CA (UroToday.com) - Delineating the genetic events contributing to the pathogenesis of clear cell renal carcinoma (ccRCC) has led to significant advances in our understanding of tumor biology and directly led to the development of targeted molecular therapy for this disease.

Sarcomatoid renal cell carcinoma (RCC) is associated with an aggressive biology and a poor prognosis. Poor-risk RCC is defined by clinical prognostic factors and demonstrates similarly aggressive behavior.

Answer questions and earn CME/CNE Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents.